e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Studies in paediatric allergy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation and efficacy of allergen immunotherapy in asthma
T. A. Papastavrou, A. M. Mavroudi, E. D. Karatza, O. D. Ourailoglou, M. J. Lioliou, J. S. Xinias, K. S. Spyroglou, J. N. Tsiouris (Thessaloniki, Greece)
Source:
Annual Congress 2005 - Studies in paediatric allergy
Session:
Studies in paediatric allergy
Session type:
Thematic Poster Session
Number:
2551
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. A. Papastavrou, A. M. Mavroudi, E. D. Karatza, O. D. Ourailoglou, M. J. Lioliou, J. S. Xinias, K. S. Spyroglou, J. N. Tsiouris (Thessaloniki, Greece). Evaluation and efficacy of allergen immunotherapy in asthma. Eur Respir J 2005; 26: Suppl. 49, 2551
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Specific allergen immunotherapy of asthma combined with allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006
Specific immunotherapy in the management of allergic asthma
Source: Annual Congress 2008 - PG2 - Asthma: natural history, risk factors and overall management
Year: 2008
Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy
vs
specific immunotherapy allone
Source: Eur Respir J 2001; 18: Suppl. 33, 431s
Year: 2001
Therapeutic approach in allergic asthma: ASIT oposit to ICS
Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2010
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 439s
Year: 2006
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Safety and efficacy of omalizumab in children with allergic asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 438s
Year: 2006
Allergen immunotherapy: therapeutic vaccines for allergic diseases
Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=409
Year: 2003
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018
Adherence to sublingual immunotherapy in patients allergic to mites
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Effects of oromucosal immunotherapy (SLIT) in children with respiratory allergy
Source: Eur Respir J 2002; 20: Suppl. 38, 525s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept